论文部分内容阅读
目的:探讨调强放疗(IMRT)治疗非小细胞肺癌(NSCLC)的疗效。方法:对2008年1月～2009年6月就诊于我科的46例Ⅰ～Ⅳ非小细胞肺癌患者应用IMRT治疗,与采用常规放疗的46例患者临床资料进行近期疗效和毒副反应的对比分析。结果:IMRT治疗组总有效率(CR+PR)为71.7%,常规放疗(RT)组为54.3%,其中完全缓解率分别为21.7%和8.7%,2组差异有统计学意义(P<0.05)。2组急性放射性食管炎发生率分别为33.0%和50%,放射性肺炎发生率分别为28.2%和43.5%,白细胞下降发生率分别为36.9%和61.0%。结论:调强放射治疗治疗非小细胞肺癌较常规放疗有更好的疗效和临床症状改善率,毒副反应轻,患者易耐受,可提高肿瘤控制率和患者生活质量。
Objective: To investigate the efficacy of IMRT in the treatment of non-small cell lung cancer (NSCLC). Methods: IMRT was performed in 46 patients with stage Ⅰ-Ⅳ non-small cell lung cancer who were treated in our department from January 2008 to June 2009, and compared with the short-term efficacy and side effects of 46 patients with conventional radiotherapy analysis. Results: The total effective rate (CR + PR) was 71.7% in IMRT group and 54.3% in conventional radiotherapy group, and the complete response rate was 21.7% and 8.7% in IMRT group (P <0.05) ). The incidence of acute radiation esophagitis was 33.0% and 50% in the two groups, the incidence of radiation pneumonitis was 28.2% and 43.5% respectively, and the incidence of leukopenia was 36.9% and 61.0% respectively. Conclusion: IMRT treatment of non-small cell lung cancer has better curative effect and improvement of clinical symptoms than conventional radiotherapy, with mild toxicity and patient tolerance, and can improve tumor control rate and quality of life of patients.